# TRIM56

## Overview
TRIM56 is a gene that encodes the tripartite motif-containing 56 protein, a member of the TRIM protein family known for its involvement in various cellular processes, including antiviral immunity and tumorigenesis. The TRIM56 protein is characterized by a tripartite motif comprising an N-terminal RING domain, B-box domains, and a coiled-coil region, which collectively contribute to its function as an E3 ubiquitin ligase. This protein plays a crucial role in the regulation of innate immune responses by modulating key signaling pathways such as the Toll-like receptor (TLR) and cGAS-STING pathways, which are essential for detecting viral infections and initiating immune responses (Wang2022Impaired; Fu2023The). Additionally, TRIM56 is implicated in various diseases, including glioma and multiple myeloma, where it influences tumor progression and immune regulation (Wang2024TRIM56:; Chen2018TRIM56). Understanding the molecular mechanisms of TRIM56 is vital for developing therapeutic strategies targeting viral infections and cancer.

## Structure
TRIM56 is a member of the TRIM protein family, characterized by a tripartite motif that includes an N-terminal RING domain, one or two B-box domains, and a coiled-coil region. The RING domain provides E3 ubiquitin ligase catalytic activity, facilitated by a conserved pattern of cysteine and histidine residues that coordinate zinc ions, essential for ubiquitin transfer (Esposito2017Structural). The B-box domains, also coordinating zinc ions, do not possess E3 catalytic activity but are implicated in protein-protein interactions and have been linked to disease when mutated (Esposito2017Structural). The coiled-coil region is crucial for TRIM homodimerization, which is necessary for the protein's function (Esposito2017Structural).

TRIM56 also contains an NHL-like domain, which is associated with RNA-binding and may play a role in gene expression regulation and RNA metabolism (Chaikuad2022Comparative). This domain forms a conserved six-bladed β-propeller structure, facilitating interactions with macromolecules such as proteins and nucleic acids (Chaikuad2022Comparative). TRIM56 is involved in the suppression of influenza virus RNA synthesis, highlighting its role in innate immune responses (Chaikuad2022Comparative). The protein may undergo post-translational modifications, such as ubiquitination, which are common in TRIM family proteins.

## Function
TRIM56 is a protein encoded by the TRIM56 gene, playing a significant role in antiviral innate immunity and tumorigenesis. It functions as an E3 ubiquitin ligase, catalyzing the ubiquitination of various proteins, which is crucial for protein activity, interactions, and localization (Fu2023The). TRIM56 is involved in the regulation of key signaling pathways, such as the Toll-like receptor (TLR) and cGAS-STING pathways, which are essential for the innate immune response. These pathways detect extracellular double-stranded RNA and cytosolic DNA, respectively, leading to the transcriptional induction of pro-inflammatory cytokines and type I interferon (IFN) to limit viral transmission (Fu2023The; Wang2022Impaired).

TRIM56 can inhibit viral RNA replication and regulate antiviral signaling in a ubiquitination-independent manner (Fu2023The). It is also involved in the monoubiquitination of cGAS, enhancing its DNA-binding activity and promoting the production of cGAMP, which is crucial for the cGAS-STING pathway (Seo2018TRIM56mediated). In resting cells, TRIM56 is located in the cytoplasm, but it can translocate to the nucleus, where it influences viral replication and immune signaling (Fu2023The). Understanding the molecular processes and cell biology of TRIM56 is crucial for developing novel antiviral drugs and therapeutic strategies against tumors (Fu2023The).

## Clinical Significance
TRIM56 has been implicated in several diseases due to alterations in its expression levels and interactions. In glioma, a type of malignant brain tumor, high TRIM56 expression is associated with poor prognosis and is linked to high-grade gliomas, IDH wild-type gliomas, and gliomas without 1p/19q codeletion. TRIM56 is involved in the activation of the PI3K-AKT and IL6-JAK-STAT3 signaling pathways, contributing to cell proliferation and immune regulation. It is also correlated with immune checkpoints and a higher tumor mutation burden, suggesting its role in creating an immunosuppressive tumor microenvironment (Yang2022TRIM56; Wang2024TRIM56:; Zhang2023TRIM56).

In multiple myeloma, TRIM56 acts as a tumor suppressor by activating the TLR3/TRIF signaling pathway, which is crucial for antiviral responses. Its expression is down-regulated in multiple myeloma cells, and its overexpression leads to increased cytokine production and apoptosis, suggesting its potential as a therapeutic target (Chen2018TRIM56).

TRIM56 also plays a protective role in nonalcoholic fatty liver disease (NAFLD) by promoting the degradation of fatty acid synthase, thereby reducing lipid accumulation and liver damage (Xu2024TRIM56). In diabetic kidney disease, TRIM56 is involved in mitochondrial dysfunction through its interaction with AMPKα, contributing to disease progression (Lv2024LncRNA).

## Interactions
TRIM56 is involved in several key interactions within the innate immune system, particularly in antiviral responses. It interacts with the STING protein, enhancing IFN-β promoter activation, which is crucial for the induction of type I interferons in response to intracellular double-stranded DNA (dsDNA) (Tsuchida2010The). TRIM56 forms a complex with STING, mediated by their C-terminal regions, but does not interact with IPS-1 (Tsuchida2010The). It also catalyzes the monoubiquitination of cGAS at lysine 335, enhancing cGAS dimerization, DNA-binding activity, and cGAMP production, which are essential for the cGAS-mediated IFNαβ production in response to DNA virus infections (Seo2018TRIM56mediated).

TRIM56 interacts with TRIF, positively regulating the TLR3-mediated interferon pathway independently of its E3 ligase activity (Fu2023The). It also catalyzes the M1-type ubiquitination of TAK1, enhancing the interaction between TAK1 and IKKα, which is crucial for NF-κB signaling (Fu2023The). These interactions highlight TRIM56's role in modulating key signaling pathways in antiviral immunity.


## References


[1. (Seo2018TRIM56mediated) Gil Ju Seo, Charlotte Kim, Woo-Jin Shin, Ella H. Sklan, Hyungjin Eoh, and Jae U. Jung. Trim56-mediated monoubiquitination of cgas for cytosolic dna sensing. Nature Communications, February 2018. URL: http://dx.doi.org/10.1038/s41467-018-02936-3, doi:10.1038/s41467-018-02936-3. This article has 151 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-02936-3)

[2. (Fu2023The) Lin Fu, Xiaotong Zhou, Qian Jiao, and Xi Chen. The functions of trim56 in antiviral innate immunity and tumorigenesis. International Journal of Molecular Sciences, 24(5):5046, March 2023. URL: http://dx.doi.org/10.3390/ijms24055046, doi:10.3390/ijms24055046. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24055046)

[3. (Yang2022TRIM56) Xu Yang, Yan Zhang, Zhiwei Xue, Yaotian Hu, Wenjing Zhou, Zhiyi Xue, Xuemeng Liu, Guowei Liu, Wenjie Li, Xiaofei Liu, Xingang Li, Mingzhi Han, and Jian Wang. Trim56 promotes malignant progression of glioblastoma by stabilizing ciap1 protein. Journal of Experimental &amp; Clinical Cancer Research, December 2022. URL: http://dx.doi.org/10.1186/s13046-022-02534-8, doi:10.1186/s13046-022-02534-8. This article has 11 citations.](https://doi.org/10.1186/s13046-022-02534-8)

[4. (Zhang2023TRIM56) Qing Zhang, Jianglin Zheng, Wenjie Wu, Haiyan Lian, Natasha Iranzad, Endi Wang, Lianhe Yang, Xuan Wang, and Xiaobing Jiang. Trim56 acts through the iqgap1-cdc42 signaling axis to promote glioma cell migration and invasion. Cell Death &amp; Disease, March 2023. URL: http://dx.doi.org/10.1038/s41419-023-05702-6, doi:10.1038/s41419-023-05702-6. This article has 6 citations.](https://doi.org/10.1038/s41419-023-05702-6)

[5. (Chaikuad2022Comparative) Apirat Chaikuad, Rezart Zhubi, Claudia Tredup, and Stefan Knapp. Comparative structural analyses of the nhl domains from the human e3 ligase trim–nhl family. IUCrJ, 9(6):720–727, September 2022. URL: http://dx.doi.org/10.1107/s2052252522008582, doi:10.1107/s2052252522008582. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1107/s2052252522008582)

[6. (Lv2024LncRNA) Zhimei Lv, Ziyang Wang, Jinxiu Hu, Hong Su, Bing Liu, Yating Lang, Qun Yu, Yue Liu, Xiaoting Fan, Meilin Yang, Ning Shen, Dongdong Zhang, Xia Zhang, and Rong Wang. Lncrna pvt1 induces mitochondrial dysfunction of podocytes via trim56 in diabetic kidney disease. Cell Death &amp; Disease, September 2024. URL: http://dx.doi.org/10.1038/s41419-024-07107-5, doi:10.1038/s41419-024-07107-5. This article has 0 citations.](https://doi.org/10.1038/s41419-024-07107-5)

[7. (Tsuchida2010The) Tetsuo Tsuchida, Jian Zou, Tatsuya Saitoh, Himanshu Kumar, Takayuki Abe, Yoshiharu Matsuura, Taro Kawai, and Shizuo Akira. The ubiquitin ligase trim56 regulates innate immune responses to intracellular double-stranded dna. Immunity, 33(5):765–776, November 2010. URL: http://dx.doi.org/10.1016/j.immuni.2010.10.013, doi:10.1016/j.immuni.2010.10.013. This article has 403 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.immuni.2010.10.013)

[8. (Wang2024TRIM56:) Bingcheng Wang, Zhihai Wang, Yuchen Li, Zehan Shang, Zihao Liu, Hao Fan, Rucai Zhan, and Tao Xin. Trim56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis. Frontiers in Immunology, January 2024. URL: http://dx.doi.org/10.3389/fimmu.2024.1327898, doi:10.3389/fimmu.2024.1327898. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2024.1327898)

[9. (Chen2018TRIM56) Ying Chen, Jing Zhao, Dengzhe Li, Jinxia Hao, Pengcheng He, Huaiyu Wang, and Mei Zhang. Trim56 suppresses multiple myeloma progression by activating tlr3/trif signaling. Yonsei Medical Journal, 59(1):43, 2018. URL: http://dx.doi.org/10.3349/ymj.2018.59.1.43, doi:10.3349/ymj.2018.59.1.43. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.3349/ymj.2018.59.1.43)

[10. (Wang2022Impaired) Dang Wang, Ruixue Wang, and Kui Li. Impaired antiviral responses to extracellular double-stranded rna and cytosolic dna, but not to interferon-α stimulation, in trim56-deficient cells. Viruses, 14(1):89, January 2022. URL: http://dx.doi.org/10.3390/v14010089, doi:10.3390/v14010089. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/v14010089)

[11. (Esposito2017Structural) Diego Esposito, Marios G. Koliopoulos, and Katrin Rittinger. Structural determinants of trim protein function. Biochemical Society Transactions, 45(1):183–191, February 2017. URL: http://dx.doi.org/10.1042/bst20160325, doi:10.1042/bst20160325. This article has 139 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20160325)

[12. (Xu2024TRIM56) Suowen Xu, Xiumei Wu, Sichen Wang, Mengyun Xu, Tingyu Fang, Xiaoxuan Ma, Meijie Chen, Jiajun Fu, Juan Guo, Song Tian, Tian Tian, Xu Cheng, Hailong Yang, Junjie Zhou, Zhenya Wang, Yanjun Yin, Wen Xu, Fen Xu, Jinhua Yan, Zhihua Wang, Sihui Luo, Xiao-Jing Zhang, Yan-Xiao Ji, and Jianping Weng. Trim56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase. Journal of Clinical Investigation, January 2024. URL: http://dx.doi.org/10.1172/jci166149, doi:10.1172/jci166149. This article has 5 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci166149)